300685 Stock Overview
Amoy Diagnostics Co., Ltd. develops and sells molecular diagnostics for oncology precision medicine in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Amoy Diagnostics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥21.27 |
| 52 Week High | CN¥26.90 |
| 52 Week Low | CN¥14.60 |
| Beta | 0.63 |
| 1 Month Change | 4.21% |
| 3 Month Change | 8.08% |
| 1 Year Change | -17.94% |
| 3 Year Change | -55.33% |
| 5 Year Change | 12.94% |
| Change since IPO | -5.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300685 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -2.8% | 3.1% | 1.7% |
| 1Y | -17.9% | -14.2% | -9.5% |
Return vs Industry: 300685 underperformed the CN Biotechs industry which returned -14.2% over the past year.
Return vs Market: 300685 underperformed the CN Market which returned -9.5% over the past year.
Price Volatility
| 300685 volatility | |
|---|---|
| 300685 Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in CN Market | 11.0% |
| 10% least volatile stocks in CN Market | 4.3% |
Stable Share Price: 300685's share price has been volatile over the past 3 months.
Volatility Over Time: 300685's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,119 | Jiemin Luo | www.amoydx.com |
Amoy Diagnostics Co., Ltd. develops and sells molecular diagnostics for oncology precision medicine in China and internationally. The company offers NGS, real-time PCR, FISH, and extraction assays. Amoy Diagnostics Co., Ltd.
Amoy Diagnostics Co., Ltd. Fundamentals Summary
| 300685 fundamental statistics | |
|---|---|
| Market cap | CN¥8.39b |
| Earnings (TTM) | CN¥268.37m |
| Revenue (TTM) | CN¥1.08b |
31.3x
P/E Ratio7.8x
P/S RatioIs 300685 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300685 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.08b |
| Cost of Revenue | CN¥181.70m |
| Gross Profit | CN¥899.93m |
| Other Expenses | CN¥631.56m |
| Earnings | CN¥268.37m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.68 |
| Gross Margin | 83.20% |
| Net Profit Margin | 24.81% |
| Debt/Equity Ratio | 3.0% |
How did 300685 perform over the long term?
See historical performance and comparison